New Delhi [India], October 9: MSN Laboratories, a leading global Indian pharmaceutical company, today announced that it is the first to launch the revolutionary JAK inhibitor molecules Tofacitinib (Tofadoz) and Upadacitinib (Upadoz) in India.
Deputy CM Shukla highlighted that the owner of the Tamil Nadu-based Sresan pharmaceuticals company, manufacturer of the Coldrif cough syrup due to which children died, was arrested, and he would be brought here on transit remand.
Earlier today, the Madhya Pradesh police arrested S Ranganathan, the owner of the Tamil Nadu-based pharmaceuticals company that manufactured the Coldrif cough syrup linked to 20 children's deaths.
Speaking to ANI, Chhindwara Superintendent of Police (SP) Ajay Pandey said, "The SIT that left from Chhindwara has arrested Sresan Pharma owner Ranganathan. He was rounded up late at night and then arrested. As part of the procedure, his medical examination will be done and other proceedi
US-based pharmaceutical company Eli Lilly and Company has announced plans to invest more than USD one billion in India over the next several years, marking one of the largest foreign investments in the country's healthcare manufacturing sector in recent years. Union Minister of Commerce and
In a letter dated October 7, the Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi emphasised the "critical importance of testing new materials, including the excipients, before their use in the manufacturing of pharmaceutical formulations."
According to Chhindwara SP, Ranganathan will be presented before the Chennai court today and will be brought to Chhindwara after securing transit remand.
In a letter to the Union Health Minister on Wednesday, the association stated that the incident raised serious questions about the safety, quality assurance, and monitoring mechanisms governing the manufacture and distribution of pharmaceutical products for children.
Health Minister Veena George announced that all medicines manufactured by Sresan Pharmaceuticals, a company based in Kanchipuram, Tamil Nadu, have been banned from distribution and sale in Kerala. The move follows action taken by the Tamil Nadu Drugs Controller to cancel the company's man
ReLife and Respifresh TR were found to have DEG more than the prescribed standard. While the standard only allows for 0.1 per cent in the medicine, ReLife contained 0.616 per cent and Respifresh TR contained 1.342 per cent, according to officials.
Tokyo [Japan], October 7: Kubota Pharmaceutical Holdings Co., Ltd. (TSE: 4596) today announced that its groundbreaking myopia management device, Kubota Glass, will make its international debut at ASEAN International Optics Fair Bangkok 2025, taking place in Bangkok, Thailand, from October 9-